Skip to content
lifestyle.streetregister.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Scynexis
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
June 30, 2026
SCYNEXIS Announces One-for-Eight Reverse Stock Split
May 25, 2026
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 24, 2026
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 23, 2026
←
Previous Page
1
2